Therapeutic developments in amyotrophic lateral sclerosis (Q40408954)

20 September 2017

title

Therapeutic developments in amyotrophic lateral sclerosis (English)

1 reference

amyotrophic lateral sclerosis

20 September 2017

main subject

0 references

author name string

Lai EC

series ordinal

1

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 April 1999

1 reference

Expert Opinion on Investigational Drugs

20 September 2017

published in

1 reference

20 September 2017

volume

8

1 reference

20 September 2017

issue

4

1 reference

20 September 2017

page(s)

347-361

1 reference

The natural history of motoneuron loss in amyotrophic lateral sclerosis

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Motor neuron disease (amyotrophic lateral sclerosis).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Onset, natural history and outcome in idiopathic adult motor neuron disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

The natural history of amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

ALS in Rochester, Minnesota, 1925-1977.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Amyotrophic lateral sclerosis. Recent advances in pathogenesis and therapeutic trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Natural history of amyotrophic lateral sclerosis in a database population Validation of a scoring system and a model for survival prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

The central nervous system in motor neurone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

A quantitative electrophysiological study of motor neurone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Preservation of a certain motoneurone group of the sacral cord in amyotrophic lateral sclerosis: its clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Cu/Zn superoxide dismutase gene mutations in amyotrophic lateral sclerosis: correlation between genotype and clinical features

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Linkage of recessive familial amyotrophic lateral sclerosis to chromosome 2q33-q35.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Amyotrophic lateral sclerosis: Part 2. Etiopathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Amyotrophic lateral sclerosis: human challenge for neuroscience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Amyotrophic lateral sclerosis. Insights from genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Recombinant growth hormone treatment of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Effect of high-dose intravenous immunoglobulin on amyotrophic lateral sclerosis and multifocal motor neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

A pilot trial of dextromethorphan in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Protirelin (thyrotropin-releasing hormone) in amyotrophic lateral sclerosis. The role of androgens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Branched-chain amino acids in the treatment of amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Levamisole is ineffective in the treatment of amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Therapeutic horizons for amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Therapeutic advances in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Amyotrophic lateral sclerosis: current and future treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Glutamate neurotoxicity and diseases of the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Glutamate dysfunction and selective motor neuron degeneration in amyotrophic lateral sclerosis: a hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Selective loss of glial glutamate transporter GLT‐1 in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Enhanced oxygen radical production in a transgenic mouse model of familial amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Glutamate transporters are oxidant-vulnerable: a molecular link between oxidative and excitotoxic neurodegeneration?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Immunoglobulins from animal models of motor neuron disease and from human amyotrophic lateral sclerosis patients passively transfer physiological abnormalities to the neuromuscular junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Long-term neuromuscular dysfunction produced by passive transfer of amyotrophic lateral sclerosis immunoglobulins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Cytotoxicity of immunoglobulins from amyotrophic lateral sclerosis patients on a hybrid motoneuron cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Calcium-permeable alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors: a molecular determinant of selective vulnerability in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Differential sensitivity of calbindin and parvalbumin immunoreactive cells in the striatum to excitotoxins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

The presence of calbindin in rat cortical neurons protects in vitro from oxydative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Effect of riluzole on focal cerebral ischemia in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Riluzole specifically blocks inactivated Na channels in myelinated nerve fibre

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Neuroprotective effects of riluzole on N-methyl-D-aspartate- or veratridine-induced neurotoxicity in rat hippocampal slices

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

A summary of mechanistic hypotheses of gabapentin pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

21 January 2018

Neurotrophic molecules

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

The changing scene of neurotrophic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Therapeutic potential of neurotrophic factors for neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Neurotrophic molecules: strategies for designing effective therapeutic molecules in neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

The response of motoneurons to neurotrophins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Clinical and molecular aspects of motoneurone diseases: animal models, neurotrophic factors and Bcl-2 oncoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

The potential of insulin-like growth factor-I as a therapeutic for the treatment of neuromuscular disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Activity-sensitive signaling by muscle-derived insulin-like growth factors in the developing and regenerating neuromuscular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Nerve sprouting in innervated adult skeletal muscle induced by exposure to elevated levels of insulin-like growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Targeted disruption of the BDNF gene perturbs brain and sensory neuron development but not motor neuron development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Targeted disruption of the trkB neurotrophin receptor gene results in nervous system lesions and neonatal death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Evidence that brain-derived neurotrophic factor is a trophic factor for motor neurons in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Ciliary neurotrophic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Ciliary neurotrophic factor prevents the degeneration of motor neurons after axotomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Renal agenesis and the absence of enteric neurons in mice lacking GDNF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Renal and neuronal abnormalities in mice lacking GDNF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Rescue of adult mouse motoneurons from injury-induced cell death by glial cell line-derived neurotrophic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Protective effects of SR 57746A in central and peripheral models of neurodegenerative disorders in rodents and primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

CEP-1347/KT7515, a JNK pathway inhibitor, supports the in vitro survival of chick embryonic neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.347

21 January 2018

Identifiers

DOI

10.1517/13543784.8.4.347

1 reference

20 September 2017

1 reference